BioStem TechnologiesBSEM +4.22%49 PB Ratio is 1.20 as of Jun. 26, 2026, which is 88% below its 10-year median of 10.32. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $139.96 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, BioStem Technologies ranks better than 78.41% on this metric.
BioStem Technologies Inc stock PB Ratio (=1.34) is close to 10-year low of 1.25.
The historical rank and industry rank for BioStem Technologies's PB Ratio or its related term are showing as below:
BSEM'
s PB Ratio Range Over the Past 10 Years
Min: 1.14 Med: 10.32 Max: 33.67
Current: 1.2
During the past 13 years, BioStem Technologies's highest PB Ratio was 33.67. The lowest was 1.14. And the median was 10.32.
BSEM's PB Ratio is ranked better than 78.41% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs BSEM: 1.20
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioStem Technologies was 48.30% per year. The lowest was -88.00% per year. And the median was -27.95% per year.
Back to Basics: PB Ratio
BioStem Technologies (OTCPK:BSEM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioStem Technologies PB Ratio Related Terms
BioStem Technologies PB Ratio Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioStem Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioStem Technologies (BSEM) has a PB Ratio of 1.20 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioStem Technologies and its competitors. This is 88% below median its historical median of 10.32. Over the past decade, BioStem Technologies' PB Ratio has ranged from 1.14 to 33.67. According to the industry distribution chart, BioStem Technologies ranks #266 out of 1232 companies in the Biotechnology industry, placing it in the top 21.6%.
Is BioStem Technologies' PB Ratio too high?
BioStem Technologies' current PB Ratio of 1.20 is 88% below median its 10-year median of 10.32. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 33.67. The Biotechnology industry median PB Ratio is 2.80. BioStem Technologies' value of 1.20 is 57.1% below this industry median. Based on the distribution chart, BioStem Technologies ranks #266 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' PB Ratio compare to TCRX and BYSI?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #266 out of 1232 companies for PB Ratio. This places BioStem Technologies in the top 22% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. BioStem Technologies' value of 1.20 is 57.1% below this benchmark. Historically, BioStem Technologies' own PB Ratio has ranged from 1.14 to 33.67 over the past decade. While the company's 10-year median is 10.32 vs. the industry median of 2.80, BioStem Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current PB Ratio of 1.20 is 57.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current PB Ratio is 1.20, which is 88% below median its own 10-year median of 10.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.59 — trading 97.4% below its estimated fair value. The current PB Ratio is 1.20, which is 88% below median its 10-year median of 10.32 and 57.1% below the Biotechnology industry median of 2.80. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current PB Ratio is 1.20 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.59 is trading 97.4% below its estimated GF Value™ of $139.96.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
PB Ratio: 1.20 (88% below median its 10-year median of 10.32)
GF Value™: $139.96 vs. price of $3.59 (97.4% below fair value)
Industry Position: 57.1% below the Biotechnology median (#266 of 1232)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
